1. Home
  2. ENTA vs ESSA Comparison

ENTA vs ESSA Comparison

Compare ENTA & ESSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • ESSA
  • Stock Information
  • Founded
  • ENTA 1995
  • ESSA 1916
  • Country
  • ENTA United States
  • ESSA United States
  • Employees
  • ENTA N/A
  • ESSA N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • ESSA Banks
  • Sector
  • ENTA Health Care
  • ESSA Finance
  • Exchange
  • ENTA Nasdaq
  • ESSA Nasdaq
  • Market Cap
  • ENTA 160.3M
  • ESSA 184.4M
  • IPO Year
  • ENTA 2013
  • ESSA N/A
  • Fundamental
  • Price
  • ENTA $7.89
  • ESSA $20.74
  • Analyst Decision
  • ENTA Buy
  • ESSA
  • Analyst Count
  • ENTA 4
  • ESSA 0
  • Target Price
  • ENTA $18.00
  • ESSA N/A
  • AVG Volume (30 Days)
  • ENTA 181.3K
  • ESSA 40.1K
  • Earning Date
  • ENTA 08-04-2025
  • ESSA 07-23-2025
  • Dividend Yield
  • ENTA N/A
  • ESSA 2.89%
  • EPS Growth
  • ENTA N/A
  • ESSA N/A
  • EPS
  • ENTA N/A
  • ESSA 1.55
  • Revenue
  • ENTA $64,462,999.00
  • ESSA $66,345,000.00
  • Revenue This Year
  • ENTA N/A
  • ESSA $9.38
  • Revenue Next Year
  • ENTA $0.48
  • ESSA N/A
  • P/E Ratio
  • ENTA N/A
  • ESSA $13.39
  • Revenue Growth
  • ENTA N/A
  • ESSA N/A
  • 52 Week Low
  • ENTA $4.09
  • ESSA $15.82
  • 52 Week High
  • ENTA $17.24
  • ESSA $22.22
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 67.33
  • ESSA 73.67
  • Support Level
  • ENTA $6.95
  • ESSA $18.62
  • Resistance Level
  • ENTA $8.23
  • ESSA $19.67
  • Average True Range (ATR)
  • ENTA 0.40
  • ESSA 0.45
  • MACD
  • ENTA 0.00
  • ESSA 0.22
  • Stochastic Oscillator
  • ENTA 75.11
  • ESSA 96.14

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About ESSA ESSA Bancorp Inc.

ESSA Bancorp Inc is a holding company, engaged in accepting deposits from the general public and investing those deposits, together with funds generated from operations and borrowings, in residential first mortgage loans (including construction mortgage loans), commercial real estate loans, home equity loans and lines of credit and commercial and industrial loans. The company offers a variety of deposit accounts, including checking, savings and certificates of deposit. The company also offers asset management and trust services and investment services. The company also offers insurance benefit consulting services through its wholly-owned subsidiary, ESSA Advisory Services, LLC.

Share on Social Networks: